All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN PD-L1 < 1% PD-L1 > 1% stage IIIa stage IIIb stage IIIc
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/adv melanoma (mML), pembrolizumab based treatment vs. anti-PD-(L)1, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMspire-170, 2020 1.06 [0.69; 1.62]
1.06 [0.69 ; 1.62 ] IMspire-170, 2020 1 0% 446 NA not evaluable progression or deaths (PFS)detailed results IMspire-170, 2020 1.15 [0.88; 1.50]
1.15 [0.88 ; 1.50 ] IMspire-170, 2020 1 0% 446 NA not evaluable DCRdetailed results IMspire-170, 2020 0.91 [0.63; 1.32]
0.91 [0.63 ; 1.32 ] IMspire-170, 2020 1 0% 446 NA not evaluable objective responses (ORR)detailed results IMspire-170, 2020 0.77 [0.50; 1.17]
0.77 [0.50 ; 1.17 ] IMspire-170, 2020 1 0% 446 NA not evaluable AE (any grade)detailed results IMspire-170, 2020 14.27 [3.34; 61.03]
14.27 [3.34 ; 61.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE (grade 3-4)detailed results IMspire-170, 2020 4.03 [2.70; 6.00]
4.03 [2.70 ; 6.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE leading to death (grade 5)detailed results IMspire-170, 2020 1.39 [0.43; 4.44]
1.39 [0.43 ; 4.44 ] IMspire-170, 2020 1 0% 436 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.14; 7.03]
0.98 [0.14 ; 7.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Anaemia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Asthenia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Constipation AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results Out of scale IMspire-170, 2020 22.68 [1.32; 388.47]
22.68 [1.32 ; 388.47 ] IMspire-170, 2020 1 0% 436 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMspire-170, 2020 4.44 [1.47; 13.42]
4.44 [1.47 ; 13.42 ] IMspire-170, 2020 1 0% 436 NA not evaluable Fatigue AE (grade 3-4)detailed results IMspire-170, 2020 1.65 [0.39; 7.00]
1.65 [0.39 ; 7.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable Headache AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Hypertension AE (grade 3-4)detailed results IMspire-170, 2020 1.77 [0.73; 4.30]
1.77 [0.73 ; 4.30 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increase AST AE (grade 3-4)detailed results IMspire-170, 2020 3.00 [0.60; 15.03]
3.00 [0.60 ; 15.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMspire-170, 2020 1.99 [0.49; 8.06]
1.99 [0.49 ; 8.06 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results IMspire-170, 2020 2.00 [0.59; 6.74]
2.00 [0.59 ; 6.74 ] IMspire-170, 2020 1 0% 436 NA not evaluable Nausea AE (grade 3-4)detailed results IMspire-170, 2020 10.02 [0.54; 184.60]
10.02 [0.54 ; 184.60 ] IMspire-170, 2020 1 0% 436 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.06; 15.80]
0.98 [0.06 ; 15.80 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pruritus AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMspire-170, 2020 6.03 [0.72; 50.50]
6.03 [0.72 ; 50.50 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash AE (grade 3-4)detailed results IMspire-170, 2020 7.83 [1.77; 34.66]
7.83 [1.77 ; 34.66 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMspire-170, 2020 7.98 [0.42; 151.89]
7.98 [0.42 ; 151.89 ] IMspire-170, 2020 1 0% 436 NA not evaluable Sepsis AE (grade 3-4)detailed results IMspire-170, 2020 12.08 [0.67; 217.70]
12.08 [0.67 ; 217.70 ] IMspire-170, 2020 1 0% 436 NA not evaluable Vomiting AE (grade 3-4)detailed results IMspire-170, 2020 2.49 [0.48; 12.97]
2.49 [0.48 ; 12.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable 0.5 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 15:39 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561